search
Back to results

Comparison of Two Multimodal Analgesia Regimens in Total Knee Arthroplasty

Primary Purpose

Postoperative Pain

Status
Terminated
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Continuous perineural infusion of ropivacaine 0.2% 5 ml/h for 48 h
Extended Release Capsule
Sponsored by
Ciusss de L'Est de l'Île de Montréal
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Postoperative Pain

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients aged 18-80 years old
  • American Society of Anesthesiology physical status I-III
  • Primary total knee arthroplasty surgery under regional anesthesia

Exclusion Criteria:

  • Chronic kidney disease (CKD) with eGFR < 60mL/min
  • Contraindications for the use of spinal anesthesia or adductor canal block : infection, sepsis, evolutive neurological disease, coagulopathy, patient refusal.
  • Chronic use of opioids (>30 mg daily morphine equivalent)
  • Documented allergy to Hydromorphone, tramadol, celecoxib, ropivacaine, pregabalin, acetaminophen and/or ketorolac
  • Patient weight < 50 kg or BMI > 40
  • Severe cardiac disease
  • Severe pulmonary disease
  • Chronic use of monoamine oxydase inhibitors
  • Pregnancy
  • Inability to give informed consent
  • Patient refusal

Sites / Locations

  • Ciusss

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Group C

Group U

Arm Description

Adductor canal block performed in the pre-operative period with 20 mL of Ropivacaïne 0.5%, followed with a continuous perineural infusion of Ropivacaïne 0.2%, 5 ml/h for 48 hours via a perineural catheter. They will also receive a placebo of Hydromorph Contin 3 mg, administered twice daily for 48h, starting on the evening after surgery

Adductor canal block performed in the pre-operative period with 30 mL of Ropivacaïne 0.5%. A catheter is inserted in the adductor canal but no perineurial infusion. The catheter is connected to a pump that is shut down. They will also receive Hydromorph Contin 3 mg PO administered twice daily for 48 h, starting on the evening after surgery. 4 doses total

Outcomes

Primary Outcome Measures

Pain score during walking (24 hours)
Verbal Numeric Scale pain score (0-10, where 0= no pain and 10= worst conceivable pain) during walking

Secondary Outcome Measures

Pain score during walking (48 hours)
Verbal Numeric Scale pain score (0-10, where 0= no pain and 10= worst conceivable pain) during walking
Pain score at rest (24 hours)
Verbal Numeric Scale pain score (0-10, where 0= no pain and 10= worst conceivable pain) at rest
Pain score at rest (48 hours)
Verbal Numeric Scale pain score (0-10, where 0= no pain and 10= worst conceivable pain) at rest
Pain score at knee flexion (24 hours)
Pain score (Verbal Numeric Scale (0-10, where 0= no pain and 10= worst conceivable pain) at knee flexion
Pain score at knee flexion (48 hours)
Pain score (Verbal Numeric Scale (0-10, where 0= no pain and 10= worst conceivable pain) at knee flexion
Degree of knee flexion (24 hours)
Knee flexion (degrees) measured using a goniometer. More degrees indicates better knee flexion
Degree of knee flexion (48 hours)
Knee flexion (degrees) measured using a goniometer. More degrees indicates better knee flexion
10 minutes walking test (24 hours)
Number of meters walked during a 10 minutes period.
10 minutes walking test (48 hours)
Number of meters walked during a 10 minutes period
Incidence of Postoperative Nausea (24 hours)
number of patients experiencing postoperative nausea
Incidence of Postoperative Vomiting (24 hours)
number of patients experiencing postoperative vomiting
Incidence of Postoperative Nausea (48 hours)
Number of patients experiencing postoperative nausea
Incidence of Postoperative Vomiting (48 hours)
Number of patients experiencing postoperative vomiting
sedation score(24 hours)
Degree of sedation experienced by patients using a sedation scale score (0-3, where 0 = awake, no sedation, 3= asleep, impossible to arouse).
sedation (48 hours)
Degree of sedation experienced by patients using a sedation scale score (0-3, where 0 = awake, no sedation, 3= asleep, impossible to arouse).)
QoR-40 (48 hours)
Measurement of quality of recovery using the QoR-40 questionnaire. A greater score indicates better recovery profile
Cumulative opioïd dose (24 hours)
Cumulative dose of hydromorphone (milligrams) consumed for postoperative pain
Cumulative opioïd dose (48 hours)
Cumulative dose of hydromorphone (milligrams) consumed for postoperative pain

Full Information

First Posted
June 15, 2019
Last Updated
January 29, 2020
Sponsor
Ciusss de L'Est de l'Île de Montréal
search

1. Study Identification

Unique Protocol Identification Number
NCT03990038
Brief Title
Comparison of Two Multimodal Analgesia Regimens in Total Knee Arthroplasty
Official Title
Comparison of Two Multimodal Analgesia Regimens for Total Knee Arthroplasty : a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2020
Overall Recruitment Status
Terminated
Why Stopped
Recruitment problems making the study completion unlikely
Study Start Date
August 1, 2019 (Actual)
Primary Completion Date
October 1, 2019 (Actual)
Study Completion Date
October 1, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ciusss de L'Est de l'Île de Montréal

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The improvement of postoperative analgesia is an important issue in orthopedic surgery, especially after total knee arthroplasty The use of a peripheral nerve block such as the adductor canal block is favored since it offers a postoperative analgesia superior to opioids, and also preserves the strength of the quadriceps, as opposed to the femoral block. The adductor canal block can be given as a single injection (single shot) or a continuous perineural infusion to extend the block's analgesic duration. It is unclear if the continuous infusion is superior to the single shot. Indeed, a high catheter dislodgement rate is observed for this location and local anesthetics could migrate into the femoral canal, resulting in quadriceps weakness. Alternatively, adequate postoperative analgesia has been shown effective with a single shot adductor canal block combined with extended release opioids. The primary objective in this study is to compare two analgesic protocols on the pain score at walk 24 hours after total knee arthroplasty. Here are the two protocols compared : Adductor canal block followed by continuous perineural perfusion for 48 hours Adductor canal block (single shot) followed by hydromorphone extended release formulation for 48 hours In addition to analgesic adjuvants administered in both groups : acetaminophen, celecoxib, pregabalin, dexamethasone and periarticular infiltration. Our hypothesis is that both protocols ensure a similar analgesia.
Detailed Description
The improvement of postoperative analgesia is an important issue in orthopedic surgery, especially after total knee arthroplasty. The early postoperative mobilization of these patients is crucial to ensure a favorable functional evolution, and this goal can't be accomplished without effective analgesia. Opioids offer an efficient pain relief, but their consumption can result in side effects that can increase the length of hospital stay. The use of a peripheral nerve block, such as the adductor canal block (BCA) is a widely favored alternative since it allows postoperative analgesia superior to opioids while preserving the strength of the quadriceps. For a long period of time, the femoral block has been the most popular peripheral nerve block for patients after a knee arthroplasty. However, this perineural block is associated with an important rate of quadriceps' weakness, which could impair the post-operative mobilization and expose the patient to a risk of falling. It has now been widely replaced by the adductor canal block. The latter has the advantage of providing analgesia at rest and during movement equivalent to the femoral block, while preserving the quadriceps strength and offering a better mobility in the first 24 hours after surgery. In opposition to the femoral block, the adductor canal block does not increase the risk of falling since it is mainly a sensitive block. The adductor canal block is an advantageous analgesic modality for patients after TKA, but it is limited since it offers only analgesia to the anteromedial aspect of the knee, sparing the lateral and posterior faces. It is common to combine this block with a periarticular knee infiltration with local anesthetics, performed by the surgical team at the end of the surgery. The two modalities combined make it possible to achieve very low pains scores at rest and during walking, compared to both techniques used separately. The adductor canal block can be administered in one unique injection or with a perineural continuous infusion, to extend the block's analgesic duration. However, it is uncertain whether there is an advantage to use a continuous infusion. There is a significant rate of catheter migrating out of the adductor canal and losing effect. There is also the possibility that the continuous infusion results in a proximal extent of local anesthetic in the femoral canal, generating quadriceps weakness that invalidates the benefits for ACB in the context of postoperative mobilization. Indeed, the location of the catheter near the surgical site predisposes it to be dislodged out of the adductor canal during surgical manipulations in a significant proportion of patients. A rate as high as 30% of catheter dislodgement on postoperative day 1 was observed. It is possible to perform the block after surgery, before the dressing is applied, but this practice tends to create delays, which are not desirable in the actual context of optimization of the OR time. In addition, perineural catheters require a strict surveillance by a specialized team and could interfere with patient mobilization because of the restriction associated with the equipment involved. It is reasonable to think that the absence of a catheter and an infusion pump offers an easier mobilization, although this has not been validated in clinical trials. Finally, continuous infusions increase the cumulative dose of local anesthetics that the patients is exposed to. In order to reduce the toxicity risk, it is necessary to reduce the periarticular infiltration doses, which could impair the quality of analgesia. Alternatively, it has been demonstrated that adequate post-operative analgesia could be obtained with an adductor canal block, combined with extended release opioids. Several clinical trials involving patients after total knee arthroplasty have shown that there is a benefit to using extended release opioids added to a multimodal analgesia protocol. Their pharmacokinetic profile ensures a more constant analgesia, while offering a safety profile similar to immediate release opioids, a lesser risk of respiratory depression and overdose. The usage of extended release opioids after TKA is justified since patients accuse moderate to severe pain during the first days after surgery, despite the use of a multimodal analgesia protocol and sustained consumption of immediate release opioids. These two protocols have not been compared. In conclusion, there is a consensus that postoperative analgesia in patients after TKA should be addressed with a multimodal analgesia protocol that includes a perineural block and analgesic adjuvants. However, the optimal composition of this protocol is not well defined. In our hospital center, the postoperative analgesia protocol for TKA includes a continuous adductor canal block for 48 hours, intravenous dexamethasone, periarticular infiltration of the posterior capsule by the surgeon and analgesic adjuvants such as acetaminophen, celecoxib and pregabalin. Study outcome and hypothesis The primary objective in this study is to compare two analgesic protocols on the pain score while walking 24 hours after total knee arthroplasty. Here are the two protocols compared : Adductor canal block followed by continuous perineural perfusion for 48 hours Adductor canal block (single shot) followed by hydromorphone extended release formulation for 48 hours In addition to analgesic adjuvants administered in both groups : acetaminophen, celecoxib, pregabalin, dexamethasone and periarticular infiltration. Our hypothesis is that both protocols ensure a similar analgesia. Our secondary issues are the proportion of patient that achieve a pain score at walk < 4, the time for the 10 m walk test, the incidence of drowsiness, nausea and vomiting and the postoperative opioid use at 24 and 48 hours postoperatively. This clinical trial is relevant since it aims to answer a frequently asked question in clinical practice, and its outcome will have a direct impact on the anesthetic practice. In addition, it aims to improve early postoperative mobilization with acceptable pain, which is important after orthopedic surgery. Methodology Study design This will be a prospective, randomized, double blind study. Population Patients undergoing elective TKA Duration of study 18 months Sample size Assuming a walking pain score at day 1 of 4.8 (± 2.3) with continuous infusion adductor canal block, periarticular infiltration and analgesic adjuvants, 69 patients per group will detect a difference of 25% between pain scores in both groups, with a power of 90% and an alpha = 0.05. In order to compensate for the losses at follow-up, a total of 150 patients will be recruited.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Two multimodal analgesic protocols will be compared. Patients will be randomized to one of two analgesic protocol: C: Single-shot adductor canal block followed by a 48h perineurial continuous infusion of ropivacaine U: Single-shot adductor canal block and post operative extended release hydromorphone for 48h (4 doses)
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Participants won't know their group because this study will use a double placebo: Group U: placebo for extended release hydromorphone (4 doses) Group C: sham perineurial infusion for 48h in group C (Perineurial catheter is connected to perineurial infusion pump but not infusion) Perineural infusion pumps will be covered with an opaque plastic bag to ensure blinding for patients and care providers Nurses and anesthesiologist and physiotherapist will be blinded to patient group allocation Investigator and outcome assessor will be blinded to group allocation
Allocation
Randomized
Enrollment
2 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group C
Arm Type
Active Comparator
Arm Description
Adductor canal block performed in the pre-operative period with 20 mL of Ropivacaïne 0.5%, followed with a continuous perineural infusion of Ropivacaïne 0.2%, 5 ml/h for 48 hours via a perineural catheter. They will also receive a placebo of Hydromorph Contin 3 mg, administered twice daily for 48h, starting on the evening after surgery
Arm Title
Group U
Arm Type
Active Comparator
Arm Description
Adductor canal block performed in the pre-operative period with 30 mL of Ropivacaïne 0.5%. A catheter is inserted in the adductor canal but no perineurial infusion. The catheter is connected to a pump that is shut down. They will also receive Hydromorph Contin 3 mg PO administered twice daily for 48 h, starting on the evening after surgery. 4 doses total
Intervention Type
Drug
Intervention Name(s)
Continuous perineural infusion of ropivacaine 0.2% 5 ml/h for 48 h
Other Intervention Name(s)
Continous naropin infusion
Intervention Description
Group C receive the intervention Group U receives the placebo See arm description
Intervention Type
Drug
Intervention Name(s)
Extended Release Capsule
Other Intervention Name(s)
Hydromorph Contin 3 mg PO BID for 48 h
Intervention Description
Group C receives a placebo for extended release hydromorphone Group U receives Hydromorph Contin 3 mg PO BID See arm description
Primary Outcome Measure Information:
Title
Pain score during walking (24 hours)
Description
Verbal Numeric Scale pain score (0-10, where 0= no pain and 10= worst conceivable pain) during walking
Time Frame
24 hours postoperatively
Secondary Outcome Measure Information:
Title
Pain score during walking (48 hours)
Description
Verbal Numeric Scale pain score (0-10, where 0= no pain and 10= worst conceivable pain) during walking
Time Frame
48 hours postoperatively
Title
Pain score at rest (24 hours)
Description
Verbal Numeric Scale pain score (0-10, where 0= no pain and 10= worst conceivable pain) at rest
Time Frame
24 hours postoperatively
Title
Pain score at rest (48 hours)
Description
Verbal Numeric Scale pain score (0-10, where 0= no pain and 10= worst conceivable pain) at rest
Time Frame
48 hours postoperatively
Title
Pain score at knee flexion (24 hours)
Description
Pain score (Verbal Numeric Scale (0-10, where 0= no pain and 10= worst conceivable pain) at knee flexion
Time Frame
24 hours postoperatively
Title
Pain score at knee flexion (48 hours)
Description
Pain score (Verbal Numeric Scale (0-10, where 0= no pain and 10= worst conceivable pain) at knee flexion
Time Frame
48 hours postoperatively
Title
Degree of knee flexion (24 hours)
Description
Knee flexion (degrees) measured using a goniometer. More degrees indicates better knee flexion
Time Frame
24 hours postoperatively
Title
Degree of knee flexion (48 hours)
Description
Knee flexion (degrees) measured using a goniometer. More degrees indicates better knee flexion
Time Frame
48 hours postoperatively
Title
10 minutes walking test (24 hours)
Description
Number of meters walked during a 10 minutes period.
Time Frame
24 hours postoperatively
Title
10 minutes walking test (48 hours)
Description
Number of meters walked during a 10 minutes period
Time Frame
48 hours postoperatively
Title
Incidence of Postoperative Nausea (24 hours)
Description
number of patients experiencing postoperative nausea
Time Frame
24 hours postoperatively
Title
Incidence of Postoperative Vomiting (24 hours)
Description
number of patients experiencing postoperative vomiting
Time Frame
24 hours postoperatively
Title
Incidence of Postoperative Nausea (48 hours)
Description
Number of patients experiencing postoperative nausea
Time Frame
48 hours postoperatively
Title
Incidence of Postoperative Vomiting (48 hours)
Description
Number of patients experiencing postoperative vomiting
Time Frame
48 hours postoperatively
Title
sedation score(24 hours)
Description
Degree of sedation experienced by patients using a sedation scale score (0-3, where 0 = awake, no sedation, 3= asleep, impossible to arouse).
Time Frame
24 hours postoperatively
Title
sedation (48 hours)
Description
Degree of sedation experienced by patients using a sedation scale score (0-3, where 0 = awake, no sedation, 3= asleep, impossible to arouse).)
Time Frame
48 hours postoperatively
Title
QoR-40 (48 hours)
Description
Measurement of quality of recovery using the QoR-40 questionnaire. A greater score indicates better recovery profile
Time Frame
48 hours postoperatively
Title
Cumulative opioïd dose (24 hours)
Description
Cumulative dose of hydromorphone (milligrams) consumed for postoperative pain
Time Frame
24 hours postoperatively
Title
Cumulative opioïd dose (48 hours)
Description
Cumulative dose of hydromorphone (milligrams) consumed for postoperative pain
Time Frame
48 hours postoperatively

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients aged 18-80 years old American Society of Anesthesiology physical status I-III Primary total knee arthroplasty surgery under regional anesthesia Exclusion Criteria: Chronic kidney disease (CKD) with eGFR < 60mL/min Contraindications for the use of spinal anesthesia or adductor canal block : infection, sepsis, evolutive neurological disease, coagulopathy, patient refusal. Chronic use of opioids (>30 mg daily morphine equivalent) Documented allergy to Hydromorphone, tramadol, celecoxib, ropivacaine, pregabalin, acetaminophen and/or ketorolac Patient weight < 50 kg or BMI > 40 Severe cardiac disease Severe pulmonary disease Chronic use of monoamine oxydase inhibitors Pregnancy Inability to give informed consent Patient refusal
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Veronique Brulotte, MD
Organizational Affiliation
Ciusss de L'Est de l'Île de Montréal
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ciusss
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H1T2M4
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Comparison of Two Multimodal Analgesia Regimens in Total Knee Arthroplasty

We'll reach out to this number within 24 hrs